Neuronetics (STIM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
9 Apr, 2026Voting matters and shareholder proposals
Election of seven directors is up for vote, with all nominees recommended by the board.
Ratification of KPMG LLP as the independent registered public accounting firm is proposed.
Advisory approval of executive compensation is included as a non-binding vote.
Approval of the 2026 Equity Incentive Plan is on the agenda.
Other business may be addressed if properly brought before the meeting.
Board of directors and corporate governance
Seven director nominees are listed for election at the annual meeting.
Executive compensation and say-on-pay
Shareholders are asked to approve, on an advisory basis, the compensation of named executive officers.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Neuronetics
- Annual meeting to vote on directors, auditor, executive pay, and new equity plan, with strong governance focus.STIM
Proxy filing9 Apr 2026 - Q4 2025 delivered strong revenue growth and cash flow, with robust 2026 growth outlook.STIM
Q4 202518 Mar 2026 - Over 20 million shares registered for resale post-acquisition, with no proceeds to the company.STIM
Registration Filing17 Mar 2026 - Acquisition and integration of Greenbrook TMS set the stage for growth and operational synergies.STIM
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Record growth in new patient starts and adolescent market expansion set stage for 2025 breakeven.STIM
The 44th Annual William Blair Growth Stock Conference1 Feb 2026 - Q2 revenue fell 7% as net loss widened, but a major merger and new financing support future growth.STIM
Q2 20241 Feb 2026 - Q3 revenue up 4% to $18.5M; Greenbrook deal approved, cost synergies, break-even by 2025.STIM
Q3 202415 Jan 2026 - Greenbrook deal closing soon, with major cost synergies and utilization growth ahead.STIM
Piper Sandler 36th Annual Healthcare Conference11 Jan 2026 - Q4 revenue up 11% to $22.5M; 2025 targets $145–$155M revenue and cash flow positivity by Q3.STIM
Q4 202426 Dec 2025